GLI GLI Quality Tool
GLI Quality Tool — Version 2.0

Writing a TB lab procedure for verifying new test strip lots

New lots of TB test strips should be treated as a change requiring objective evidence, not as a routine delivery to put straight into service. Manufacturing variation, transport conditions, expiry limits and packaging differences can affect performance. A written procedure tells staff how to verify each lot before patient use and creates a defensible record of the decision.

The procedure should fit the assay actually used by the laboratory. It may cover lateral-flow antigen tests, strip-based serology or another manufacturer-supplied format, while sample preparation, application, reading and interpretation rules must follow the current instructions for use (IFU). State which product and IFU version the procedure governs rather than trying to replace manufacturer requirements.

The GLI Quality Tool’s four-phase roadmap and twelve Quality Systems Essentials offer a useful framework: verification belongs within document control, equipment management, assessment and continual improvement. Australian laboratories should also align the procedure with local accreditation and regulatory arrangements, including NATA accreditation against AS/NZS ISO 15189 where applicable and TGA requirements for devices supplied in the Australian market.

Define the purpose, product and scope

Begin with a purpose statement: demonstrate that a new lot performs acceptably before any strip is used for patient testing. Identify the device, manufacturer, catalogue number, strip lot, buffer or reagent lot where separate, authorised intended use and storage limits. The procedure should apply to every new lot, including split deliveries and emergency supplies.

Set boundaries clearly. State which specimen types, test readers, operators and laboratory sites are covered, and exclude activities the IFU does not authorise. A changed specimen, reader software or intended use requires a documented impact assessment and, where needed, additional validation rather than simple inclusion by wording.

Place the controlled procedure in the quality management system. Link it to receipt, testing, review, nonconformance and release forms, and identify its owner, approving authority, revision and effective date. This connects lot verification to the laboratory’s broader quality system.

Assign responsibilities and prepare the lot

Name the responsible people rather than relying on shared habit. The person receiving the lot checks seals, quantity, lot number, expiry date and damage; the tester prepares and runs the panel; the reviewer checks compliance; and an authorised approver releases or rejects the lot. Deputies and after-hours arrangements should be stated.

Quarantine the shipment in the manufacturer-required storage conditions until acceptance. Check the Australian label, IFU, packaging integrity, supplied controls and local distributor identifiers. Confirm that the exact device is listed in the Australian Register of Therapeutic Goods or covered by an applicable exemption under the Therapeutic Goods (Medical Devices) Regulations 2002.

Account for Australian operating conditions. Sites from Sydney to Perth and Darwin may receive deliveries through different couriers or during weekends; hot-climate storage and transit delays can expose products to unsuitable temperatures. Record the condition on arrival and follow the IFU for rejecting affected stock, even when the shipment looks intact.

Before testing, confirm that operators are authorised and competent, readers are maintained according to manufacturer requirements, and controls are in date. Many Australian teams use an electronic laboratory information system alongside controlled printed worksheets; choose one traceable record location for this procedure.

Select materials and define acceptance criteria

Choose verification materials that challenge the assay without relying only on obvious positive and negative samples. Manufacturer controls establish basic performance, while validated non-patient materials can represent strong and weak reactions. The quality manager should approve the panel and its rationale before results are viewed.

Use controls and validated non-patient materials representing negative, strong-positive and weak-positive results, especially a weak positive near the decision limit. Where the IFU allows comparison, test the new and currently accepted lots in parallel using the same material. If residual patient specimens are unavoidable, use governance-approved, de-identified samples under the Privacy Act 1988 and applicable state or territory privacy law.

Define acceptance criteria before testing. They should include valid control lines, expected classifications, agreement with the comparator or reference method, permitted invalid and discordant rates, read-time compliance and any minimum repeat testing required. Base sample numbers on validation evidence, precision, expected error rates and manufacturer guidance; never revise the criteria after seeing inconvenient results.

Perform and interpret verification testing

Prepare the work area and materials as if they will enter routine service. Record room conditions where they affect the assay, verify equipment status, prepare a coded panel plan and test the current accepted lot alongside the new lot. Randomise testing order across operators or days when the design requires challenge from realistic variation.

For each run, record strip and reagent lots, expiry dates, operator, equipment identifier, specimen or control ID, preparation time, reading time and raw observations. Read every strip within the IFU window and record control-line and test-line status. Treat an invalid strip as an invalid result, not a negative; repeat only as the IFU and local procedure permit, retaining the original record.

Independent review helps protect against transcription and interpretation error. The GLI guidance on double-checking smear results illustrates a structured approach to a second competent reader; apply the same principle to strip reading, while recognising that smear reading and strip interpretation remain separate technical tasks.

Review evidence and authorise lot release

Calculate results against the predefined criteria and compare discrepant findings with the current lot, reference method or repeat investigation. Record absolute counts as well as percentages, because a small verification panel can make one invalid strip materially affect the decision. Do not average away a serious discordance.

The review record should identify all kit components used, deviations, the decision, acceptance and release signatures, and the date the lot became available for patient use. Link supporting run sheets, validated images, instrument records and training evidence. Retain records according to the laboratory’s approved retention schedule and applicable legal and accreditation requirements.

Only an authorised approver should release the lot. Mark the container or electronic inventory as released and record quantities, locations and any split lot identifiers. Keep rejected stock clearly quarantined and prevent it from being selected accidentally. A release decision applies to the lot tested, not to future shipments from the same supplier.

Reliability checks that prevent repeat failures

If any acceptance criterion is missed, quarantine the entire affected lot, stop patient use and notify the responsible supervisor and supplier as required. Assess whether invalid results, discordance, damaged packaging or a temperature excursion has affected other lots, and document the nonconformance before testing resumes.

A failed lot should trigger a risk-based corrective action process. The GLI example of corrective action planning after failed proficiency tests shows how root causes, owners, deadlines and effectiveness checks can be assigned. Keep results produced by the suspect lot under review through the laboratory’s incident process; never release or amend reports without authorised clinical and quality review.

Use these controls to make the written procedure dependable:

Review the procedure at least annually and whenever the IFU, device, reader, specimen workflow or regulatory requirement changes. Version superseded copies, withdraw them from points of use and retain an archive. Periodic review turns individual lot decisions into a controlled learning cycle.

Make verification part of routine practice

Treat each verified lot as one point in a broader control strategy. Trend concordance, invalid rates, reader failures, complaints and time from receipt to release by supplier and lot. These trends can reveal drift that a one-time pass would miss. Include lot data in internal quality review and share relevant findings with the supplier, public health program or manufacturer.

A visual management board can display released and quarantined lots, unresolved excursions, overdue corrective actions and recurring invalid rates. Keep patient identifiers off the board, use controlled lot identifiers and assign an owner and due date to each exception. Review the display at the routine quality meeting so release status and corrective work remain visible to busy staff.

Approve the procedure against the current IFU, assign its owner, train every operator and pilot it with the next delivery before routine use. Require a documented release decision for each new lot and begin patient testing only after approval. Release verified lots, quarantine uncertain lots and use every result to strengthen the laboratory’s quality management system.